TCR2 Therapeutics Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 24.293 million compared to USD 16.716 million a year ago. Net loss was USD 24.312 million compared to USD 16.245 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.67 a year ago. For the half year, operating loss was USD 45.885 million compared to USD 32.942 million a year ago. Net loss was USD 45.824 million compared to USD 31.751 million a year ago. Basic loss per share from continuing operations was USD 1.22 compared to USD 1.32 a year ago.